🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn about variability in LVEF assessments and its impact on cardiotoxicity detection. Suero-Abreu et al (journalofnuclearcardiology.org/article/S1071-…) Editorial (journalofnuclearcardiology.org/article/S1071-…) #CTRCD #LVEF #ERNA Alfonso Waller Giselle A. Suero Abreu, MD PhD #cardioonc ASNC Society #cvnuc

Join us for an engaging session, moderated by Anne Blaes & Tomas G. Neilan, MD, MPH, at this year's #MSKCardioOncCME, where we'll explore the latest advancements in #LungCancer care and their impact on #Cardiovascular health. Register by March 1 for early rates 🔜 bit.ly/MSKCardioOnc20…

🚨 irAE aficionados! Still time to register for the inaugural irAE consortium (3/7) and the CME course on irAE (3/7-3/8) - both hybrid! Also a few seats left for an inperson benefit dinner to launch a patient advocacy group on Thur March 7th #dineandgive ghlf.org/irae-consortiu…

This AHA Science statement is the result of an effort by a multidisciplinary of adult and pediatric experts from around the nation including #CardioOnc and #Hematology to finally bring you evidence-based guidance on the cardiovascular management of patients undergoing BMT.

🫀Don't miss this original research from a great team in JACC Journals! 📰tinyurl.com/bu4kxxnf Amin Nassar, MD Toni Choueiri, MD george demetri Tomas G. Neilan, MD, MPH Aakash Desai, MD, MPH, FASCO Hanna Dalla Pria, MD Ryan Denu, MD, PhD #JACCCardioOnc

Interested in studying how the brain controls our cardiovascular health? Come and join our growing lab at MGH and HMS as a PostDoc. Expect full support, scientific freedom, and a very friendly environment. Check here for details x.com/jobRxiv/status… Please RT!

Congrats Sarju Ganatra, MD, FACC. Another amazing accomplishment

Congratulations Salim S. Hayek, MD. That is a well deserved and amazing accomplishment.

Congrats @JJheart_doc. Like so many on here, I have been very lucky to call you a colleague, mentor and friend. So extremely well deserved.

Exclusion of pts w/ prior #cancer diagnosis from CV trials poses a significant (and peristent) barrier! 🌎🌍🌏There is an increase in pts with co-existing cancer &CVD ➡️growing gap in knowledge regarding these promising CV drugs! International Cardio-Oncology Society #CardioOnc

Very proud of rising ⭐️Ginny Sun for her poster on #LLM to detect #irae of #ICI therapy based free text notes on #ASCO24 🏁9 sec’s per chart to find 90+ % complex toxicities is nothing short of phenomenal. By far outperformed ICD codes. Amazing team Kerry Reynolds Tomas G. Neilan, MD, MPH

Fantastic to be a part of this collaborative effort which made the cover of Nature Reviews Cardiology!! Thanks to Zoltan Varga and team members Marinos Kallikourdis, PhD Tomas G. Neilan, MD, MPH Wouter Meijers @.TamasGergely nature.com/nrcardio/

Congrats Han Zhu. That is so well deserved and in an area of limited research.

Very proud of amazing Ginny Sun, MD from MGH IM Residents. Co-led with Kerry Reynolds from Mass General Cancer Center. Large language models with an excellent sensitivity and specificity for several key ICI associated adverse events and in 9 secs. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

In nature, a collaboration with Kerry Reynolds, Alexandra-Chloé Villani Lab, Steve Blum, Daniel Zlotoff from Mass General Cancer Center, MassGeneral Medicine and others. Immune response in checkpoint myocarditis. Sincere thanks to the patients and families. MGH Cardiovascular Research Center International Cardio-Oncology Society. Mass General Heart nature.com/articles/s4158…

⭐️NEW PAPER OUT in nature⭐️ 🫀What is the relationship between the immune responses in the heart, blood, and tumor in patients with inflammation in the heart resulting from cancer immunotherapy (irMyocarditis)? This 🧵 breaks down the key findings 1/n nature.com/articles/s4158…

🌟 TCR clonality heart-tumor 🔍 Expanded heart clones ≠ expanded tumor clones 👉 Distinct T-cell clones suggest that T-cell responses in these patients may be directed against distinct antigens, providing hope to disentangle irMyocarditis from anti-tumor responses. 5/n

🌟 Antigens in irMyocarditis 🔍 None of the 52 most expanded TCRs from across 8 irMyocarditis patients responded to the heart proteins α-myosin, troponin I, or T. 👉 This suggests that the most expanded intracardiac T cell clones recognize novel autoantigen(s). 7/n

We 👉 Identify novel biomarkers of irMyocarditis onset and severity. 👉 Implicate non-immune cells in pathogenesis. 👉 Suggest that Tcell responses in the heart are distinct from those in tumors. We hope that our findings will help to develop strategies to mitigate irMyocarditis

Cancer therapies can carry CV risks, but current safety tools fall short. The Cardiac Safety Research Consortium led a multi-stakeholder think tank to improve CV safety reporting in oncology trials. Read the findings + next steps in #JACCCardioOnc: jacc.org/doi/10.1016/j.…